WATERBURY - The state Department of Public Health confirmed there is an open investigation of Abbott Terrace Health Center, ...

The Nifty Pharma has gained around 37% year to date. The growth continues to be led by the US sales and well supported by ...

Abbott India said that it has signed a non-exclusive patent license agreement with Takeda Pharmaceuticals Company to commercialize Vonoprazan, a novel molecule in the gastrointestinal therapy area, ...

Piper Sandler initiates coverage on Abbott with an Overweight rating, citing its diversified business model, strong medtech ...

Fintel reports that on September 19, 2024, Piper Sandler initiated coverage of Abbott Laboratories ( NYSE:ABT) with a Overweight recommendation.

For Abbott Laboratories, average sales revenue over the last 5 years has been $62.56 Billion, so in the context of the Graham analysis the stock has impressive sales revenue. Originally the threshold ...

AbbVie is a pharmaceutical firm with a strong exposure to immunology (with Humira, Skyrizi, and Rinvoq) and oncology (with Imbruvica and Venclexta). The company was spun off from Abbott in early 2013.

Foreign exchange fluctuation is a major headwind for ABT, as a considerable percentage of its revenues comes from outside the ...

Piper Sandler initiated coverage on Abbott Laboratories (NYSE:ABT) with an "overweight" rating and a price target of $131 per ...

Adam Maeder, an analyst from Piper Sandler, has initiated a new Buy rating on Abbott Laboratories (ABT). Adam Maeder has given his Buy rating ...

In a report released yesterday, Larry Biegelsen from Wells Fargo maintained a Buy rating on Abbott Laboratories (ABT – Research Report), ...

Even more alarming is AbbVie's payout ratio of 216.7%, far surpassing the peer average of 141%. This sky-high figure means ...